KRAS and neoplasm: In NSCLC, SOD1 supports KRAS-driven tumor growth, and its inhibition—genetically or by the SOD1-targeting agent ATN-224—reduces tumor burden and increases oxidative stress, with minimal toxicity in normal tissues [174].